Cyclocarbamate and cyclic amide derivatives

A compound having the structure:

• wherein:
• A and B are independent substituents selected from the group consisting of S, CH or N;
• wherein:
• (i) when A is S, B is CH or N;
• (ii) when B is S, A is CH or N;
• (iii) A and B cannot both be CH;
• and
• (iv) when A and B both equal N, one N may be optionally substituted with an C1 to C6 alkyl group;
• R1 and R2 are independent substituents selected from the group consisting of H, C1 to C6 alkyl, substituted C1 to C6 alkyl, C2 to C6 alkenyl substituted C2 to C6 alkenyl, C2 to C6 alkynyl, substituted C2 to C6 alkynyl, C3 to C8 cycloalkyl, substituted C3 to C8 cycloakyl, aryl, substituted aryl, heterocyclic, substituted heterocyclic, CORA, and NRBCORA;
• or R1 and R2 are fused to form:
• a) a C-based saturated 3 to 8 membered spirocyclic ring;
• or
• b) a C-based 3 to 8 membered spirocyclic having one or more carbon-carbon double bonds ring;
• or
• c) a 3 to 8 membered spirocyclic ring containing one to three heteroatoms selected from the group consisting of O, S and N;
• RA is H, C1 to C3 alkyl, substituted C1 to C3 alkyl, aryl substituted aryl, C1 to C3 alkoxy, substituted C1 to C3 alkoxy, C1 to C3 aminoalkyl, or substituted C1 to C3 aminoalkyl;
• RB is H, C1 to C3 alkyl, or substituted C1 to C3 alkyl;
• R3 is H, OH, NH2, C1 to C6 alkyl substituted C1 to C6 alkyl, C3 to C6 alkenyl, substituted C1 to C6 alkenyl, alkynyl, substituted alkynyl, or CORC;
• RC is H, C1 to C4 alkyl, substituted C1 to C4 alkyl, aryl, substituted aryl, C1 to C4 alkoxy, substituted C1 to C4 alkoxy, C1 to C4 aminoalkyl, or substituted C1 to C4 aminoalkyl;
• R4 is a substituted benzene ring containing the substituents X, Y and Z as shown below,
• X is selected from the group consisting of halogen, CN, C1 to C3 alkyl, substituted C1 to C3 alkyl, C1 to C3 alkoxy, substituted C1 to C3 alkoxy, C1 to C3 thioalkyl, substituted C1 to C3 thioalkyl, C1 to C3 aminoalkyl, substituted C1 to C3 aminoalkyl, NO2, C1 to C3 perfluoroalkyl, 5 or 6 membered heterocyclic ring containing in its backbone 1 to 3 heteroatoms, CORD, OCORD, and NRECORD;
• RD is H, C1 to C3 alkyl, substituted C1 to C3 alky, aryl, substituted aryl, C1 to C3 alkoxy, substituted C1 to C3 alkoxy, C1 to C3 aminoalkyl, or substituted C1 to C3 aminoalkyl;
• RE is H, C1 to C3 alkyl, or substituted C1 to C3 alkyl;
• Y and Z are independently selected from the group consisting of H, halogen, CN, NO2, C1 to C3 alkoxy, C1 to C4 alkyl, and C1 to C3 thioalkyl;
• or
• R4 is a five or six membered ring having in its backbone 1, 2, or 3 heteroatoms selected from the group consisting of O, S, SO, SO2 and NR5, the five or six membered ring being optionally substituted by one or two independent substituents selected from the group consisting of H, halogen, CN, NO2, C1 to C4 alkyl, C1 to C3 alkoxy, C1 to C3 aminoalkyl, CORF, and NRGCORF;
• RF is H, C1 to C3 alkyl, substituted C1 to C3 alkyl, aryl, substituted aryl, C1 to C3 alkoxy, substituted C1 to C3 alkoxy, C1 to C3 aminoalkyl, or substituted C1 to C3 aminoalkyl;
• RG is H, C1 to C3 alkyl, or substituted C1 to C3 alkyl;
• R5 is H, C1 to C3 alkyl, or C1 to C4 CO2alkyl;
• Q is O, S, NR6, or CR7R8;
• R6 is selected from the group consisting of CN, C1 to C6 alkyl, substituted C1 to C6 alkyl, C3 to C8 cycloalkyl, substituted C3 to C8 cycloalkyl, aryl, substituted aryl, heterocyclic, substituted heterocyclic, and SO2CF3;
• R7 and R8 are independent substituents selected from the group consisting of H, C1 to C6 alkyl, substituted C1 to C6 alkyl, C3 to C8 cycloalkyl, substituted C3 to C8 cycloalkyl, aryl, substituted aryl, heterocyclic, substituted heterocyclic, NO2, CN, and CO2R9;
• R9 is C1 to C1 alkyl;
• or CR7R8 may comprise a six membered ring of the structure below:
• W is O;
• wherein said substituted alkyl, alkenyl, and alkynyl groups have one or more substituents selected from the group consisting of halogen, CN, OH, NO2, amino, aryl, heterocyclic, substituted aryl, substituted heterocyclic, alkoxy, aryloxy, substituted alkyloxy, alkylcarbonyl, alkylcarboxy, alkylamino, arylthio;
• said substituted aryl groups have one or more substituents selected from the group consisting of halogen, CN, OH, NO2, amino, alkyl, cycloalkyl, alkenyl, alkynyl, alkoxy, aryloxy, substituted alkyloxy, alkylcarbonyl, alkylcarboxy, alkylamino, or arylthio;
• said substituted alkyloxy groups have one or more substituents selected from the group consisting of halogen, CN, OH, NO2, amino, alkyl, cycloalkyl, alkenyl, alkynyl, alkoxy, aryloxy, alkylcarbonyl, alkylcarboxy, alkylamino, or arylthio;
• wherein said heterocyclic group is selected from a stable 4- to 7-membered monocyclic or a stable multicyclic heterocyclic ring consisting of carbon atoms and from one to four heteroatoms selected from the group including N, O, and S atoms;
• and
• said substituted heterocyclic groups have one or more substituents selected from the group which includes halogen, CN, OH, NO2, amino, alkyl, substituted alkyl, cycloalkyl, alkenyl, substituted alkenyl, alkynyl, alkoxy, aryloxy, substituted alkyloxy, alkylcarbonyl, alkylcarboxy, alkylamino, or arylthio,
• or a pharmaceutically acceptable salt thereof.